Adlai Nortye Biopharma Co., Ltd.

Quick facts

Phase 3 pipeline

• Buparlisib & Paclitaxel · Oncology
  Buparlisib inhibits PI3K signaling while paclitaxel stabilizes microtubules to prevent cell division, together targeting cancer cell proliferation through complementary pathways.

Phase 1 pipeline

• AN0025
• AN2025
• AN4005-dose level 0
• AN4005-dose level 1
• AN4005-dose level 2
• AN4005-dose level 3
• AN4005-dose level 4
• AN4005-food effect
• AN9025 oral capsule

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Adlai Nortye Biopharma Co., Ltd. portfolio CI brief
• Adlai Nortye Biopharma Co., Ltd. pipeline updates RSS